Physician profile
Page Hefner
NPI 1023584323
$4,249.05
in general payments reported to CMS, 2019-2025
40 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,005 · 2022: $1,005 · 2023: $847 · 2024: $652 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.87 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $420.19 | 2021-2023 | |
| Novo Nordisk INC | $293.06 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $263.23 | 2023-2025 | Gemtesa, Aptiom |
| Otsuka America Pharmaceutical, INC. | $203.93 | 2022-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $202.01 | 2021-2025 | Airsupra, Farxiga |
| Avanir Pharmaceuticals, INC. | $195.92 | 2021-2022 | |
| Glaxosmithkline, LLC. | $179.07 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $150.69 | 2021-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $141.02 | 2021-2025 | Nayzilam, Briviact |
| Janssen Pharmaceuticals, INC | $133.18 | 2021-2024 | Spravato |
| Urovant Sciences INC | $124.99 | 2022 | |
| Sunovion Pharmaceuticals INC. | $122.28 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.91 | 2022-2025 | Jardiance |
| Pfizer INC. | $116.90 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Page Hefner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.